Centre to review medicine price regulation norms soon
One of the key agenda before the committee will be to design a price moderation framework for emerging and precision therapies to facilitate their timely reach to the needy patients.
pharmaceutical industry
March 2024
December 2023
October 2023
September 2023
August 2023
April 2023
New rules bar unethical marketing by pharma companies
The government issued a directive instructing pharmaceutical industry associations to ensure "strict compliance" with the UCPMP 2024.
Akums Drugs and Pharmaceuticals Limited: Endeavour to deliver Quality Medicines and Advancing Pharmaceutical Manufacturing
Established with a clear vision, Akums remains unwavering in its commitment to excel in the pharmaceutical industry.
Piramal Pharma shares rise 8% after Q2 results
The company reported a consolidated net profit of ₹5 crore in the July to September quarter of FY24. The company had reported a loss of ₹37 crore in the same period last year.
Pharma's Richest Ride Demand Tailwinds
The stellar run continues post-Covid as promoters reap benefits of growth in India and new launches in key markets.
New scheme for R&D in pharma, medtech
Nine established pharma companies will be selected on the basis of their willingness to carry out research in six priority areas with academic collaboration in government research institutions.
Medical device makers wary of new Bill to regulate drugs, devices and cosmetics
In a letter to Mansukh Mandaviya, AIMED says the final draft of the Bill does not propose an independent regulatory regime for medical devices
Sun Pharma profit declines 2% to ₹2,022.5 cr; revenue up 11% in Q1
The revenue from operations of the Mumbai-based company stood at ₹11,940.8 crore, up 10.9% as against 10,761.7 crore in the Q1 of FY23.
Glenmark Pharma to pay $87.5 mn to settle lawsuits in U.S.
Glenmark Pharmaceutical said that the settlement will make clear that the company denies allegations by the Plaintiff groups.
Serum Institute to double its investment in Biocon subsidiary to $300 mn
As per the new arrangement, Biocon Biologics will have access to 100 million doses of vaccines annually together with the distribution rights to Serum Institute’s vaccine portfolio.
